Cullinan Therapeutics Announces Q4 2026 Clinical Data Timelines

What Happened
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) filed a Form 8-K on September 24, 2026 (press release furnished as Exhibit 99.1) announcing anticipated clinical data updates to be shared in the fourth quarter of 2026. The company said it will present multiple data sets across its immunology and oncology programs, including Phase 1 updates for CLN-978, velinotamig, and CLN-049. The report was signed by CFO Mary Kay Fenton.

Key Details

• CLN-978 (immunology): Company will share both multi-dose and single target dose regimen data from ongoing Phase 1 trials in patients with treatment-refractory moderate-to-severe systemic lupus erythematosus (SLE), difficult-to-treat rheumatoid arthritis (RA), and treatment-refractory moderate-to-severe Sjögren’s disease in December 2026.
• Velinotamig (immunology): Multi-dose regimen data from the Phase 1 dose-escalation trial in SLE (conducted by Chongqing Genrix Biopharmaceutical in China) will be presented in a poster session at American College of Rheumatology (ACR) Convergence 2026 in November 2026.
• CLN-049 (oncology): Updated dose-escalation data from the ongoing Phase 1 trial in relapsed/refractory acute myeloid leukemia (AML) will be shared in December 2026.
• Regulatory note: The disclosures were made under Regulation FD and documented in the 8-K filed Sept. 24, 2026.

Why It Matters
These near-term clinical readouts are material milestones for Cullinan’s pipeline—Phase 1 multi-dose and dose-escalation data can help investors assess safety, tolerability and early signs of activity, and they often act as catalysts for biotech stocks. The timing (ACR in November and multiple updates in December) gives investors a clear short-term timeline for potential news flow. As these are early-stage (Phase 1) results, they provide data signals but not definitive proof of efficacy or regulatory outcomes.